I’m finding it increasingly fascinating how experimental designs in the lab don’t always translate smoothly into clinical applications. For instance, the recent study on CRISPR effects on sickle cell disease showed promise but faced complications in patient trials. How do you all think we can bridge these gaps more effectively?
It’s like trying to fit a square peg in a round hole. We might need to focus more on patient feedback during trials — real-world experiences can highlight issues lab studies miss. What do you think @researchfan, could more input from patients help?
, this drives me nuts too! I think incorporating continuous patient monitoring tech could help catch issues sooner in trials, like those complications seen with CRISPR for sickle cell. What do you think, @mindy_r76?